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Abstract
Hypoxia-inducible factor 1 (HIF-1) is a master regulator of cellular adaptation to hypoxia and has been suggested as a
potent therapeutic target in cerebral ischemia. Here we show in an ischemic stroke model of rats that inhibiting HIF-1 and
its downstream genes by 3-(5’-hydroxymethyl-2’-furyl)-1-benzylindazole (YC-1) significantly increases mortality and enlarges
infarct volume evaluated by MRI and histological staining. Interestingly, the HIF-1 inhibition remarkably ameliorates
ischemia-induced blood-brain barrier (BBB) disruption determined by Evans blue leakage although it does not affect brain
edema. The result demonstrates that HIF-1 inhibition has differential effects on ischemic outcomes and BBB permeability. It
indicates that HIF-1 may have different functions in different brain cells. Further analyses show that ischemia upregulates
HIF-1 and its downstream genes erythropoietin (EPO), vascular endothelial growth factor (VEGF), and glucose transporter
(Glut) in neurons and brain endothelial cells and that YC-1 inhibits their expression. We postulate that HIF-1-induced VEGF
increases BBB permeability while certain other proteins coded by HIF-1’s downstream genes such as epo and glut provide
neuroprotection in an ischemic brain. The results indicate that YC-1 lacks the potential as a cerebral ischemic treatment
although it confers certain protection to the cerebral vascular system.
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Introduction
Since hypoxia inducible factor 1 (HIF-1) was discovered as a
master regulator in hypoxia about twenty years ago, extensive
research has revealed that HIF-1a, the regulatable subunit of HIF-
1, is induced in the brain under hypoxic/ischemic conditions [1].
For example, systemic hypoxia, whatever its duration (1, 3, or 6
hours (hrs)), increased the nuclear content of HIF-1a in mouse
brain [2]. HIF-1a was significantly induced in rat cerebral cortex
after 1 hr of recovery from cardiac arrest and remained elevated
for over 12 hrs [3]. A more recent study showed a biphasic
activation of HIF-1 after stroke that lasted for up to 10 days [4].
Furthermore, HIF-1a appeared to be mostly induced in the
penumbra, the salvageable tissue, in an ischemic brain [5].
Although it is conclusive that ischemia induces the expression of
HIF-1, the role of HIF-1 in an ischemic brain is still controversial.
On the one hand, HIF-1 regulates the expression of a broad range
of genes that facilitate cellular adaptation to low oxygen
conditions. Its targets include genes that code for molecules
participating in erythropoiesis, cell proliferation, and energy
metabolism [6–8]. Each of these functions potentially contributes
to neuronal survival in ischemia. Indeed, HIF-1 has been reported
to protect neurons from apoptosis caused by oxidative stress [9]
and focal cerebral ischemia [10–12]. Furthermore, neuron-specific
knockdown of HIF-1a increased tissue damage and reduced
survival rate of mice subjected to middle cerebral artery occlusion
(MCAO) [4]. On the other hand, several groups have reported
opposite effects of HIF-1 in cerebral ischemia. For instance,
Halterman et al. reported that HIF-1a coordinated the activity of
p53 in driving ischemia-induced delayed neuronal death instead of
providing neuroprotection [13]. Using the same neuron-specific
HIF-1a knock-out mice as in the previous study of Baranova et al.
[4], Helton et al. observed that the knock-out of HIF-1a reduced
ischemic damage [14].
As a transcription factor, HIF-1 exerts its effects through
proteins coded by its downstream genes such as erythropoietin (epo),
vascular endothelial growth factor (vegf), and glucose transporter (glut), etc.
These downstream genes may express differently and exert
different functions in different cell types. For example, VEGF
has been reported to have different effects on cell and tissue
injuries. On the one hand, it might directly counteract the
detrimental neurological effects associated with stroke [15,16].
VEGF supports the survival of primary motor neurons from
hypoxia-induced cell death by binding with neuropilin-1, a
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development [17]. On the other hand, VEGF promotes blood-
brain barrier (BBB) permeability by altering tight junctions under
ischemic and inflammatory conditions [18,19]. Suppressing VEGF
by HIF-1 inhibitors improves BBB permeability as observed by
Yeh et al [18]. Understanding cell-type dependent effects of HIF-1
will undoubtedly shed new lights on its role in cerebral ischemia
and provide potential approaches to promote its beneficial effect
and reduce its detrimental function.
In the present study, we determined the effects of inhibiting
HIF-1 by YC-1 (3-(5’-hydroxymethyl-2’-furyl)-1-benzylindazole,
Fig. 1), an established HIF-1 inhibitor, on ischemic outcomes in a
rat model of transient cerebral ischemia with the following
parameters: infarct volumes and BBB permeability. Furthermore,
we studied the effect of YC-1 on the expression of HIF-1
downstream genes vegf, epo, and glut-1, 3 in neurons and brain
endothelial cells after cerebral ischemia. The experiments were to
reveal the differential effects of HIF-1 in different brain cells in
cerebral ischemia. This would provide experimental evidence to
understand the intriguing effects of HIF-1 in ischemic stroke.
Materials and Methods
Animal model
All procedures using animals were approved by the Institutional
Animal Care and Use Committees of University of New Mexico
(protocol 05HSC045) and University of Kansas (protocol 192–01)
and conformed to the NIH Guidelines for use of animals in
research. Male Sprague-Dawley rats, 280–310 g, were from
Charles River Laboratory (Wilmington, MA). Animals were
maintained in a climate-controlled vivarium with a 12-hr light-
dark cycle with free access to food and water. Rats were
acclimated to the environment for 7 days before the experiments.
For all surgical and MRI scan procedures, 4.0% isoflurane in
N2O:O2 (70%:30%) was used for anesthesiainduction, and 2.0% for
anesthesia maintenance. Physiological parameters (e.g., heart rate,
respiratory rate, and blood pressure) were monitored during the
procedure using a SAII Monitoring System (MRI-Compatible
Model 1025, Small Animal Instruments, Inc. Stony Brook, NY).
Core (rectal) temperature was maintained at 37.560.5uCu s i n ga
heating pad.Ultra-miniaturefiberopticsensorswereused to provide
minimally invasive, continuous monitoring of blood pressure and
heart rate by inserting the optic fiber tip into the left femoral artery.
Middle cerebral artery occlusion (MCAO) followed by reper-
fusion was conducted using an intraluminal model as previously
described [20]. Briefly, external carotid artery (ECA), internal
carotid artery (ICA), and pterygopalatine artery of ICA were
exposed. A silicone rubber-coated monofilament nylon suture was
inserted into the ICA via a slit on the ECA. The suture was
advanced along the ICA to the extent of 18 to 19 mm from the
bifurcation. Reperfusion was produced by gently withdrawing the
suture until the suture tip reached the bifurcation and the incision
closed. After surgery, the animals were allowed to recover from
anesthesia while being given food and water ad libitum.
Buprenorphine was used as post-operative analgesia. For all
animals used in this study, successful MCAO was confirmed by
laser Doppler flowmetry (LDF) (Moor Instruments, Wilmington,
DE) as described in the literature [21]. During ischemia regional
cerebral blood flow dropped to 16.261.7% of the pre-ischemic
level; and after reperfusion the blood flow was restored to
89.564.0% of pre-ischemic level. Animals that died during
reperfusion were excluded from measuring infarct size, BBB
permeability, and HIF-1a expression. Mortality rate was calcu-
lated for each group and used as an important parameter for the
disadvantageous effect of the HIF-1a inhibitor.
Experimental groups
Totally 90 Sprague-Dawley (SD) male rats were randomly
assigned to the following three groups: YC-1 (without MCAO,
n=5), MCAO (n=40), and MCAO pretreated with YC-1
(n=45). In the MCAO (control group) and MCAO + YC-1
groups, 15 rats were used for infarct size measurement by MRI
and TTC staining; 15 rats for BBB permeability evaluation; and
10-15 rats for Western blotting and immunostaining (Table 1).
Administration of the HIF-1 inhibitor YC-1
YC-1 (Cayman Chemical Company, Ann Arbor, MI), dissolved
in a solution of 1% dimethyl sulfoxide (DMSO), was administered
at 2 mg/kg body weight through femoral vein at 24 hr and
30 min prior to the onset of ischemia. Rats in control groups
received equivolume injections of the DMSO solution. To inhibit
HIF-1, researchers have used various dosages of YC-1 ranging
from 1 to 30 mg/kg BW [18,22,23]. We chose the double
injections at 2 mg/kg based on our preliminary analyses of HIF-
1a expression after the treatments. As shown in Figure 2, ischemia
(MCAO 90 min with 24 h reperfusion) induced a strong up-
regulation of HIF-1a in the ipsilateral cortex, and the YC-1
pretreatments markedly inhibited the expression of HIF-1a.
Western blot analysis
Samples were obtained from the MCA territory cortex on the
ischemic sides (ipsilateral) and non-ischemic sides (contralateral)
using the corpus callosum as a ventral landmark. Tissues were
homogenized in an ice-cold RIPA buffer with 1 mg/ml of a
protease inhibitor cocktail (Thermo scientific, Rockford, IL, USA).
The homogenates were centrifuged at 14,000 rpm for 15 min at
4uC; and the supernatants were collected. Assays to determine the
protein concentration of the supernatants were subsequently
performed with a BCA kit (Micro BCA, Pierce). The supernatants
were fractionated in an 8% SDS-polyacrylamide gel and
transferred to a nitrocellulose membrane. Membranes were
blocked in PBS containing 5% nonfat dry milk and 0.01% Tween
Figure 1. Chemical structure of the HIF-1 inhibitor YC-1.
doi:10.1371/journal.pone.0027798.g001
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overnight at 4uC. The primary antibodies for western blotting
were HIF-1a (Novus Biologicals, Littleton, CO), VEGF (sc-507,
Santa Cruz, Santa Cruz, CA), EPO (sc-7956, Santa Cruz), and
GLUT-3 (ab53095, Abcam, Cambridge, MA, USA). Their
secondary antibody was goat anti-rabbit IgG-HRP (sc-2030,
Santa Cruz). As an internal control, the same membrane was
incubated with an antibody specifically for b-actin (Santa Cruz,
1:1000) after being stripped. Secondary antibody for actin was also
the goat anti-rabbit IgG-HRP (sc-2030, Santa Cruz). The blots
were detected by chemiluminescence with enhanced chemilumi-
nescence reagent (ECL; Amersham Pharmacia Biotech).
Measurement of infarct size by magnetic resonance
imaging and TTC staining
The rats were transported to the MRI room next to the surgery
room at the end of 24-hr reperfusion and placed in the isocenter of
the magnet before the imaging session. MRI was performed on a
4.7 T Biospecs MR scanner (Bruker Biospin, Billerica, MA). An
actively shielded gradient coil with a 120-cm inner diameter was
used. The animals were kept in the same position throughout
imaging. For each animal, we performed T2-weighted MRI by
using a rapid acquisition with refocused echos sequence. Image
data were then transferred to a workstation running Linux for
further processing. From the T2-weighted magnetic resonance
images, we calculated the volume of infarction using ImageJ.
After MRI scans, the brains were removed and sectioned into
2 mm slices. The slices were incubated in a 2% solution of TTC in
0.1 M PBS (pH 7.4) at 37uC for 30 min and fixed in 10%
formalin. TTC staining has been widely used to reflect accurately
the extent of irreversible ischemic damage in cerebral tissues in
rats [24]. TTC-stained brain sections were photographed using a
digital camera (Powershot 400 digital camera, Canon). The infarct
size was calculated by the researcher (Saeid Taheri) blind to the
treatments given; and the percentage of the infarct area with
respect to the total area was digitally quantified by ImageJ. To
compensate for the effect of brain edema, the corrected infarct
area was calculated as previously described [25]. The edema
volume was calculated by measuring the volumes of the affected
(VIpsi) and contralateral (VContra) hemispheres and using the
formula: edema volume=VIpsi2VContra [26].
Immunohistochemical staining
After 24-hr reperfusion, rats were transcardially perfused with
ice-cold PBS under anesthesia and then with 4% paraformalde-
hyde. Brains were isolated and fixed overnight in 4% paraformal-
dehyde. The brains were then embedded in O.C.T. compound
(Sakura Finetek USA, Torrance, CA) and sectioned coronally at
10 mm thickness using a vibrating microtome (Leica Microsystems,
Bannockburn, IL). After they were washed and the nonspecific
binding sites were blocked with PBS containing 0.05% triton-
X100 and 0.25% BSA for 45 min, the brain slices were incubated
with primary antibodies against HIF-1a (04–1006, Millipore,
Billerica, MA), VEGF (sc-507, Santa Cruz, Santa Cruz, CA), EPO
(sc-7956, Santa Cruz), GLUT-3 (ab53095, Abcam, Cambridge,
MA, USA), and GLUT-1 (ab652, Abcam, Cambridge, MA)
together with the primary antibodies against NEUronal Nuclei
(NeuN, MAB377, Millipore) and platelet endothelial cell adhesion
molecule-1 (PECAM-1, CBL468, Millipore) in the blocking
solution at 4uC overnight. After three washes, the slices were
incubated with fluorescent secondary antibodies (donkey anti-
rabbit Alexa 488 and goat anti-mouse Alexa 488, Molecular
Probes, Carlsbad, CA). After washing, the slices were mounted
with Vectashield medium (H-1000, Vector Laboratories, Burlin-
game). Images were captured under a Leica DMI 4000B
fluorescent microscope.
Determination of blood-brain barrier permeability
Evans blue dye (100 mg/kg, Sigma) was injected into femoral
vein 2 hrs after the onset of reperfusion according to a previous
report [18]. At the end of hr reperfusion, rats were perfused with
saline through the left ventricle until colorless perfusion fluid was
obtained from the right atrium. After decapitation, the brain was
removed from the skull; and the cortex from each hemisphere
was dissected. Samples were weighed and soaked in ml of 50%
trichloroacetic acid solution. After homogenization and centrifu-
gation, the extracted Evans blue dye was diluted with ethanol
(1:3); and fluorescence intensity was measured at 620 nm and
680 nm for excitation and emission, respectively, using a
fluorescence reader. The tissue content of Evans blue dye was
quantified from a linear standard curve derived from known
amounts of the dye and was expressed as micrograms per gram of
tissues.
Statistical analysis
The results are presented as means with a standard error of
mean. Differences between the groups were established using the
least significant difference (LSD) test or ANOVA. Significance was
assessed at the p,0.05 level.
Table 1. YC-1-induced mortality of MCAO rats and group sizes for final analyses.
Groups Initial Group Size Failed MCAO Death After Successful MCAO Group Size for Final Analyses
MCAO MRI 15 2 1 12
BBB 15 3 0 12




YC-1+MCAO MRI 15 1 5 9
BBB 15 0 6 9




aIn this MCAO group, four animals were excluded due to a lack of obvious neurological deficits and one due to bleeding during the procedure.
b In YC-1+MCAO group,
one was excluded due to a lack of obvious neurological deficits.
c Death rate after successfully completed MCAO.
doi:10.1371/journal.pone.0027798.t001
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YC-1 suppressed the expression of HIF-1a and its down-
stream genes in an ischemic brain
To verify that the YC-1 doses administered to rats wereeffectivein
inhibiting HIF-1, protein levels of HIF-1a and its downstream genes,
epo,vegf,a n dglut-3, in the contralateral and the ipsilateralhemispheres
of ischemic brains were analyzed by westernblotting after the animals
were subjected to 90 min MCAO and 24 hr reperfusion. As shown in
Figure 2A and 2B, ischemia significantly increased the level of HIF-
1a in the ipsilateral hemisphere, compared to the contralateral
hemisphere. The increase was remarkably inhibited by YC-1 in both
contralateral and ipsilateral hemispheres. Similarly, increases in the
expression of VEGF, EPO, and GLUT-3 in ischemic brains were
suppressed by the YC-1 treatment (Fig. 2C-E). These results indicate
that the doses of YC-1 administration effectivelysuppressed ischemia-
induced expression of HIF-1a and its down-stream genes in the rat
model of ischemic stroke.
Figure 2. Effect of YC-1 on the expression of HIF-1 in ischemic brains. The protein levels of HIF-1a and its down-stream proteins EPO, VEGF,
and GLUT-3 were analyzed by western blotting in brains from rats subjected to 90 min ischemia and 24 hr reperfusion. Rats received YC-1 (2 mg/kg,
i.v.) at 24 h and 30 min prior to the onset of ischemia. (A) Representative Western blots of HIF-1a and its down-stream proteins. (B) Quantification of
the HIF-1a protein level. (C) Quantification of the VEGF protein level. (D) Quantification of the EPO protein level. (E) Quantification of the GLUT-3
protein level. Values were normalized to b-actin and contralateral hemispheres of control animals. Values are means 6 SEM, n=5. #p,0.05 vs. the
contralateral hemisphere of control animals, *p,0.05 vs. the ipsilateral hemisphere of control animals.
doi:10.1371/journal.pone.0027798.g002
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ischemia
YC-1 at 2 mg/kg did not cause death in the five negative
control animals (without MCAO). As listed in Table 1, YC-1
significantly increased mortality of MCAO rats. There were 16
deaths in YC-1 treated rats received a successful MCAO,
indicating a mortality rate of 36.4% (16/44). Only did one die
among the MCAO rats without YC-1 treatments, indicating a
mortality rate of 2.9% (1/35).
YC-1 increased brain tissue damage after ischemia
T2 weighted MRI was used to determine the progression of
brain tissue damage of MCAO rats. A T2 weighted scan images
indicate change and damage in brain tissues [27]. The merit of the
MRI is that the images of the brain reflect real-time conditions and
allows us to monitor infarct progression in the same animal. To
reveal the infarct progression in a MCAO rat, we first collected a
series of time-dependent T2 images on the same animals (Fig. 3A).
At each time point, the infarct area of YC-1-treated animals was
significantly larger that of the control animals (i.e., MCAO without
YC-1). Figure 3B demonstrates T2 images of a serial of brain
sections after reperfusion for 24 hrs. In each brain section, YC-1
increased the infarct area. The infarct volume was calculated
based on the area of hyperintensity in these T2-weighted images.
Total, striatal, and cortical infarct volumes of YC-1-treated
MCAO rats were 557.4661.0, 172.2625.2, and 385.26
43.0 mm
3, respectively (Fig. 3C). Within the control group, these
volumes were 163.4637.5, 68.7624.9, and 94.6627.4 mm
3,
respectively.
We also performed TTC staining, a classic approach in stroke
research, to evaluate brain damage caused by MCAO and YC-1.
A series of TTC staining of brain sections is shown in Figure 3B.
The infarct volume measured by TTC staining demonstrated that
YC-1 induced a more severe infarction. The infarct volume in YC-
1 pretreated group was 492.8667.3 mm
3 vs. 131.6647.4 mm
3 in
control group. As shown in Figure 3D, the percentages of infarct
volume from the whole brain volume in YC-1 and control groups
were 43.565.6% and 15.161.4%, respectively. Brain edema was
also calculated after MCAO and 24 hours reperfusion (Fig. 3E).
There was no significant difference between YC-1 and control
groups in edema volume (62.0622.3 mm
3 in YC-1 group vs.
56.7626.8 mm
3 in control group).
YC-1 inhibited ischemia-induced increase in BBB
permeability
Evans blue dye was used to serve as a marker of albumin
extravasation in evaluating the effect of YC-1 on BBB permeabil-
ity. Representative images of Evans blue dye in wet brain tissues is
shown in Figure 4A. Evans blue leakage increased significantly in
the ipsilateral hemisphere (20.062.0 mg/g) of brains from rats
subjected to 90 min MCAO and 24 hr reperfusion, compared to
the contralateral side (0.760.3 mg/g). Administration of YC-1
dramatically reduced the Evans blue leakage in the ipsilateral side
to 6.064.0 mg/g, indicating a 70% reduction (Fig. 4B). These data
suggest that YC-1 protected BBB from hyperpermeability induced
by MCAO and reperfusion.
YC-1 inhibited the expression of HIF-1a in neurons in
ischemic brains
The above results clearly indicate that inhibiting HIF-1 by YC-1
caused damaging effect on the brain tissue (enlarged infarct) and
protective effect on the BBB (improved permeability) determined
by Evans blue leakage. To understand the mechanisms responsible
for the distinguished effects of YC-1, we analyzed the expression of
HIF-1a and its down-stream genes epo, vegf, and glut-3 in neurons
and endothelial cells in ischemic brains. To explore the neuron-
specific expression of HIF-1a and other genes after MCAO with
or without the presence of YC-1, double immunohistostaining was
performed with neuron marker NeuN. Figure 5A is a typical
TTC–stained brain slice and shows the selected locations for
imaging. As shown in Figure 5B, the HIF-1a level was extensively
up-regulated in neurons in the ipsilateral hemisphere 24 hrs after
MCAO. YC-1 significantly reduced HIF-1a expression in the
ischemic neurons. The expression of VEGF, EPO and GLUT-3,
which are transcriptionally activated by HIF-1, were also
significantly increased in the neurons in the ipsilateral hemisphere,
compared to that in the contralateral hemisphere (Fig. 5C-E). The
staining of the three proteins in the neurons of ipsilateral
hemisphere was remarkably reduced by YC-1 treatment. Results
from these immunostaining indicate that YC-1 inhibited the
expression of HIF-1a and its targeted genes in neurons, which may
contribute to the enlarged brain infarct in YC-1-treated MCAO
rats.
YC-1 inhibited the expression of HIF-1a and VEGF in
brain endothelial cells
To explore the expression of HIF-1a and its downstream genes
after MCAO in brain endothelial cells, double immunohistostain-
ing was performed with the endothelial marker PECAM-1. As
shown in Figure 6A, HIF-1a was up-regulated in cells in the
ipsilateral hemisphere after 90 min MCAO and 24 hr reperfusion.
Some of the HIF-1a positive cells were co-localized with PECAM-
1, indicating HIF-1a expression was elevated in endothelial cells.
YC-1 significantly decreased the endothelial HIF-1a expression.
Figure 6B demonstrates that the VEGF expression was dramat-
ically increased and highly co-localized with endothelial cells in the
ipsilateral hemisphere. YC-1 decreased the overall staining of
VEGF in both ipsilateral and contralateral hemisphere. The
expression of EPO did not seem increased in the endothelial cells
of an ischemic brain (Fig. 6C). In addition, the expression of
glucose transporter 1 was remarkably increased by ischemia and
co-localized with endothelial cells. YC-1 suppressed the glucose
transporter expression efficiently. These results indicate that
ischemia increased endothelial expression of HIF-1a, which
seemed to increase the expression of VEGF and GLUT-1 but
not EPO in endothelial cells.
Discussion
Here we show that ischemia induces the expression of HIF-1
and the proteins coded by its downstream genes epo, vegf, and glut in
both neurons and brain endothelial cells. YC-1 is able to suppress
the expression. Most significantly, we demonstrate that HIF-1
inhibition by YC-1 has differential effects on brain injury in
ischemic stroke (i.e., enlarged infarct volume and improved BBB
permeability).
VEGF is the best defined protein that is downstream of HIF-1
in vascular biology [28]. Besides being the most prominent
member of the angiogenic growth factor family, VEGF has been
known since the 1980s as a vascular permeability factor that
increases vascular permeability [29]. More recent studies have
shown that VEGF causes brain vascular leakage in pathological
conditions such as hypoxia and ischemia [18,30,31], possibly by
regulating tight junction proteins such as zona occludens 1,
claudin-5 [32,33], and occludin [34]. In this study, we observed
significant increase in VEGF expression in neurons and micro-
vessels in an ischemic brain. As shown in Figure 6B, the alignment
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Inhibiting HIF-1 by YC-1 significantly reduces VEGF expression
in brain microvessels that is upregulated by ischemia and
subsequently improves BBB permeability. This observation is in
line with the previous report by Yeh et al. that suppressing HIF-1
prevents BBB damages [18]. These results are robust in supporting
the concept that HIF-1 promotes BBB damage during cerebral
ischemia, possible through upregulating VEGF expression. In
addition, we observe that the expression of EPO does not co-
localize to the expression of PECAM-1. The lack of EPO
Figure 3. Effect of YC-1 on brain tissue damage of MCAO rats. Brian damage was estimated by MRI and TTC staining after rats were subjected
to 90 min ischemia and 24 hr reperfusion. Animals received YC-1 (2 mg/kg, i.v.) at 24 h and 30 min prior to the onset of ischemia. (A) Representative
MRI images showing time-dependent progression of infarct volumes. T2 weighted MRI images were collected at 0, 3, 6, 12, and 24 hr after MCAO
with white area representing infarct area. (B) Representative TTC staining (lower panel) and T2 (upper panel) images of brain sections of a MCAO rat.
The brain was sectioned from the 4 mm position from the frontal pole and continued in 2-mm interval to 10 mm. (C) Quantification of infarct volume
with T2-weighted MRI images of rat brain (n=12 (control), 9 (YC-1)). (D) Quantification of brain damage estimated by TTC stained sections (n=12
(control), 9 (YC-1)). (E) Quantification of brain edema volume estimated by TTC stained sections (n=12 (control), 9 (YC-1)).Values are means 6 SEM.
*p,0.05 vs. control. #p,0.05 vs. control striatum.
%P,0.05 vs. control cortex.
doi:10.1371/journal.pone.0027798.g003
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endothelial cells.
However, this BBB protection resulting from HIF-1 inhibition
by YC-1 contributes little to the overall brain tissues injury
induced by cerebral ischemia. Our results clearly demonstrate that
YC-1 significantly increases brain infarct volume and mortality in
the ischemic stroke model. This suggests that the presence of HIF-
1 is critical in promoting neuronal survival during ischemia and
reperfusion. Among the genes regulated by HIF-1, epo and glut
have extensively studies; and their neuroprotective role has been
consistent in the literature [9,11,35–38]. In agreement with these
previous reports, we observe significant upregulation of EPO and
GLUT-3 in neurons after ischemia, which is suppressed by YC-1.
This result suggests that decreasing EPO and GLUT-3 account for
YC-1-mediated exaggeration of brain damage caused by ischemia.
Furthermore, VEGF is also upregulated in neurons of an ischemic
brain and might counteract detrimental ischemic injuries [15,16],
indicating a complex role of VEGF in different types of cells.
Edema volume has a deleterious impact on the morbidity and
mortality after stroke through increasing intracranial pressure and
impairing cerebral perfusion and oxygenation during reperfusion
[39]. Another piece of evidence indicating that YC-1 cannot
ameliorate brain injury after stroke is that YC-1 does not
significantly change the edema volume after MCAO and
reperfusion (Fig. 3E). This seems contradictory to the results that
YC-1 decreases the BBB permeability defined by the extravasation
of Evens blue (albumin). The following may explain the seemingly
conflicting results. The edema volume (brain swelling) after stroke
is mainly determined by the extravasation of water and solutes
from plasma due to the increased BBB permeability, which is
termed as vasogenic edema [40]. However, BBB has different
permeability to water and solutes with different molecular weights
[41]. The permeability to larger molecules (e.g. albumin) is easier
to be maintained than those with smaller molecular (e.g. sucrose
and water) during BBB damage [41]. The ischemia-caused
increase in permeability to larger molecules might result from
different molecular changes, compared to that to small molecules
such as water. It has been reported that another HIF-1 inhibitor,
2ME2, could successfully inhibit the BBB permeability to a soluble
protein IgG after MCAO and reperfusion in mice, but only
induced a 1% change in the water content of the brain [42]. Our
results indicate that inhibiting HIF-1 by YC-1 reduces the
permeability to albumin, but it does not change the permeability
to water and cannot inhibit the formation of brain edema after
stroke.
Giving its potential effects in ischemia, HIF-1 has been a target
for understanding mechanisms of cell death and developing novel
treatments in stroke. It is of great interests in testing the effect of
HIF-1 inhibition and upregulation on brain injuries caused by
ischemia. One example of HIF-1 inhibitors is YC-1. Growing
evidence suggests that YC-1 exerts an inhibitory effect on the
accumulation of HIF-1a induced by hypoxia, iron chelation, and
proteasomal inhibition [43–45]. YC-1 may directly degrade HIF-
1a protein by inducing the degradation of C-terminal of HIF-1a
protein [46]. It can also suppress the translation of HIF-1a
through PI3K/Akt/mTOR/4E-BP pathway [47]. YC-1 has been
reported to inhibit the expression of HIF-1 downstream genes such
as epo and vegf [43]. YC-1 has widely been used as a HIF-1 blocker
in research. It has been demonstrated that YC-1 effectively inhibits
HIF-1 expression in heart [48], kidney [49], and brain [18]. YC-1
has been shown to reduce disturbances of BBB permeability
caused by ischemia by inhibiting HIF-1 expression and suggested
as a potential stroke treatment agent [18]. However, the effect of
YC-1 on the outcome of cerebral ischemia such as infarct volume
has not been tested before. Our data demonstrates that although it
ameliorates BBB permeability disturbances caused by ischemia,
YC-1 exaggerates ischemic brain damages in terms of infarct
volume and mortality. This observation provides novel evidence
for the pharmacological effects of YC-1 in ischemic stroke and
indicates that YC-1 lacks the potential as a cerebral ischemic
treatment although it confers protection to the cerebral vascular
system.
It needs to be pointed out that although it is well accepted that
YC-1 is an effective HIF-1 inhibitor, it is not a specific HIF-1
Figure 4. Effects of YC-1 on the BBB permeability of MCAO rats. BBB permeability was estimated by Evans blue leakage after rats were
subjected to 90 min ischemia and 24 hr reperfusion. Animals received YC-1 (2 mg/kg, i.v.) at 24 h and 30 min prior to the onset of ischemia. (A)
Representative images of Evans blue extravasation in a whole brain and coronal sections (bregma +0.70 mm). (B) Quantification of Evens blue
leakage in ipsilateral and contralateral hemispheres of MCAO rats (n=12 (control), 9 (YC-1)). Values are means 6 SEM. *p,0.05 vs. control.
doi:10.1371/journal.pone.0027798.g004
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intracellular concentration of cGMP though enhancing the activity
of soluble guanylate cyclase [50]. Nonetheless, inhibition of soluble
guanylate cyclase did not change the effect of YC-1 on blood brain
permeability [18]. Furthermore, it has been reported that no
serious toxicity was observed in nude mice treated with YC-1 over
a 2-week period and that YC-1 has no toxic effect on the normal
growth of rat optic nerve and PC12 cells in vitro [44,51].
A significant focus of stroke research has been on the
development of therapeutic strategies that prevent neuronal death
and improve recovery. However, to date, few successful thera-
peutic strategies have emerged. HIF-1, as a gene transcriptional
regulator induced in hypoxia, has been discussed at length for its
roles in brain tissues during ischemia. Although detrimental effects
of HIF-1 have been observed in ischemic brains, regulating HIF-
1a induction and the genes induced by HIF-1 is a highly
promising therapeutic strategy for cerebral ischemia [6,52-54] due
to their endogenous adaptive responses to hypoxia and ischemia.
HIF-1 induces expressions of a wide range of genes; and the
induction and functions of these genes may depend on the specific
cell types. As demonstrated in this study, HIF-1 may function
differently in different cells. Future studies need to focus on specific
types of cells and cellular targets to better understand the role of
HIF-1 in stroke as well as other pathological conditions.
Figure 5. Effect of YC-1 on HIF-1 expression in neurons in ischemic brains. The protein levels of HIF-1a and its down-stream genes were
analyzed by double immunostaining with the neuronal marker NeuN after rats were subjected to 90 min ischemia and 24 hr reperfusion. Rats
received YC-1 (2 mg/kg, i.v.) at 24 h and 30 min prior to the onset of ischemia. (A) TTC-stained rat brain coronal section. Labeled square areas
represent locations of immuno images. (B) Double immunostaining of HIF-1a (green) and NeuN (red). (C) Double immunostaining of EPO (green) and
NeuN (red). (D) Double immunostaining of VEGF (green) and NeuN (red). (E) Double immunostaining of GLUT-3 (green) and NeuN (red). Scale bar,
53 mm.
doi:10.1371/journal.pone.0027798.g005
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PLoS ONE | www.plosone.org 8 November 2011 | Volume 6 | Issue 11 | e27798In summary, our results provide novel evidence that HIF-1
function differently in different cells depending on the functions of
the proteins coded by its downstream genes in the specific type of
cells. The results also indicate that YC-1 lacks the potential as a
cerebral ischemic treatment although it confers protection to the
cerebral vascular system.
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